Herantis Pharma Plc, Press Release, 9 March 2023 at 09:00 A.M. EET
Herantis Pharma Plc (“Herantis”), developing disease-modifying therapies for Parkinson’s disease, today announced participation in the following conferences:
Location: Basel, Switzerland
Dates: March 20th – 22nd, 2023
Attendees: CEO Antti Vuolanto, DSc and CSO Dr. Henri Huttunen, PhD
AD/PD 2023: International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders
Location: Gothenburg, Sweden
Dates: March 28th – April 1th, 2023
- Poster Presentation by Head of Nonclinical Pharmacology at Herantis, Natalia Kulesskaya, PhD.
Title: HER-096 Is a Novel Brain-Penetrating Peptidomimetic That Promotes Proteostasis and Reduces Neuroinflammation in Aged Mouse Model of Synucleinopathy
- Presentation by Per Svenningsson, MD, PhD, Karolinska University Hospital, Principal Investigator of Herantis’ CDNF in the First-in-Human Clinical Trial.
Title: Phase 1 First-in-Man Clinical Trial of Intraputamenal CDNF in Parkinson’s Disease
If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us directly at firstname.lastname@example.org.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com